Two Sigma Investments LP raised its stake in shares of Editas Medicine Inc (NASDAQ:EDIT) by 347.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 141,931 shares of the company’s stock after buying an additional 110,201 shares during the period. Two Sigma Investments LP owned about 0.30% of Editas Medicine worth $3,229,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. We Are One Seven LLC acquired a new position in shares of Editas Medicine during the 4th quarter worth approximately $40,000. Bronfman E.L. Rothschild L.P. lifted its holdings in Editas Medicine by 48.7% in the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 3,055 shares of the company’s stock valued at $70,000 after acquiring an additional 1,000 shares during the last quarter. Ancora Advisors LLC acquired a new position in Editas Medicine in the third quarter valued at approximately $127,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its holdings in Editas Medicine by 34.2% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 5,160 shares of the company’s stock valued at $113,000 after acquiring an additional 1,314 shares during the last quarter. Finally, HBK Sorce Advisory LLC acquired a new position in Editas Medicine in the third quarter valued at approximately $203,000. Institutional investors and hedge funds own 70.17% of the company’s stock.
NASDAQ:EDIT traded up $0.08 during trading hours on Friday, hitting $25.80. The company’s stock had a trading volume of 866,073 shares, compared to its average volume of 741,937. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.44 and a quick ratio of 10.44. Editas Medicine Inc has a 52-week low of $17.80 and a 52-week high of $41.43. The firm has a market capitalization of $1.27 billion, a PE ratio of -11.07 and a beta of 2.53.
A number of research firms have commented on EDIT. Evercore ISI began coverage on Editas Medicine in a research note on Thursday, April 11th. They set an “outperform” rating on the stock. ValuEngine cut Editas Medicine from a “hold” rating to a “sell” rating in a research note on Monday, February 4th. BidaskClub raised Editas Medicine from a “sell” rating to a “hold” rating in a research report on Monday, April 1st. Zacks Investment Research lowered Editas Medicine from a “buy” rating to a “hold” rating in a research report on Wednesday, January 9th. Finally, SunTrust Banks reaffirmed a “buy” rating on shares of Editas Medicine in a research report on Monday, December 31st. Five analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $37.60.
In other news, insider Vickesh Myer sold 3,000 shares of the stock in a transaction dated Wednesday, February 20th. The shares were sold at an average price of $20.42, for a total transaction of $61,260.00. Following the completion of the sale, the insider now owns 3,000 shares in the company, valued at $61,260. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Andrew A. F. Hack sold 6,895 shares of the stock in a transaction dated Monday, February 4th. The stock was sold at an average price of $21.39, for a total transaction of $147,484.05. Following the sale, the chief financial officer now owns 6,895 shares of the company’s stock, valued at approximately $147,484.05. The disclosure for this sale can be found here. Insiders sold 12,895 shares of company stock valued at $282,244 in the last 90 days. 5.20% of the stock is currently owned by insiders.
Editas Medicine Company Profile
Editas Medicine, Inc operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments.
See Also: What is the yield curve?
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.